These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8243034)

  • 1. Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination.
    Standiford HC; Walsh TJ; Drusano GL; Tatem BA; Townsend RJ
    Diagn Microbiol Infect Dis; 1993; 17(2):135-42. PubMed ID: 8243034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates.
    Arathoon EG; Hamilton JR; Hench CE; Stevens DA
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1655-9. PubMed ID: 2285277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome.
    Walsh TJ; Standiford HC; Reboli AC; John JF; Mulligan ME; Ribner BS; Montgomerie JZ; Goetz MB; Mayhall CG; Rimland D
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1334-42. PubMed ID: 8328783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent methicillin-resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers.
    Aspinall SL; Friedland DM; Yu VL; Rihs JD; Muder RR
    Ann Pharmacother; 1995; 29(7-8):694-7. PubMed ID: 8520082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing rate and serum bactericidal activity of oxacillin, rifampin and ciprofloxacin against Staphylococcus aureus.
    Moretti MV; Fiorio M; Pasticci MB; Moretti A; Baldelli F; Pauluzzi S
    Microbiologica; 1989 Oct; 12(4):297-306. PubMed ID: 2586332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin.
    Walsh TJ; Auger F; Tatem BA; Hansen SL; Standiford HC
    J Antimicrob Chemother; 1986 Jan; 17(1):75-82. PubMed ID: 3633267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM; Rojtman AD
    Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of novobiocin and rifampin alone and in combination against oxacillin-resistant Staphylococcus aureus.
    Johnston BL; Kwok RY; Mulligan ME
    Diagn Microbiol Infect Dis; 1987 Nov; 8(3):137-47. PubMed ID: 3440369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.
    Drusano GL; Townsend RJ; Walsh TJ; Forrest A; Antal EJ; Standiford HC
    Antimicrob Agents Chemother; 1986 Jul; 30(1):42-5. PubMed ID: 3752982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of eleven antimicrobial agents against methicillin-, methicillin- and rifampin-resistant Staphylococcus aureus.
    Chokkavelu V; Chandrasekar P; Rolston K; LeFrock JL; Schell RF
    Chemotherapy; 1984; 30(2):97-101. PubMed ID: 6559665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization.
    Peterson LR; Quick JN; Jensen B; Homann S; Johnson S; Tenquist J; Shanholtzer C; Petzel RA; Sinn L; Gerding DN
    Arch Intern Med; 1990 Oct; 150(10):2151-5. PubMed ID: 2222100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.
    Hackbarth CJ; Chambers HF; Sande MA
    Antimicrob Agents Chemother; 1986 Apr; 29(4):611-3. PubMed ID: 3707110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.
    Tan TQ; Mason EO; Ou CN; Kaplan SL
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2401-6. PubMed ID: 8285624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of novobiocin against methicillin-resistant Staphylococcus aureus.
    Walsh TJ; Hansen SL; Tatem BA; Auger F; Standiford HC
    J Antimicrob Chemother; 1985 Apr; 15(4):435-40. PubMed ID: 3847438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.
    Garcia R; Raad I
    Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):933-6. PubMed ID: 9031876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations.
    Bayer AS; Lam K
    J Infect Dis; 1985 Jan; 151(1):157-65. PubMed ID: 3965588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization.
    Simor AE; Phillips E; McGeer A; Konvalinka A; Loeb M; Devlin HR; Kiss A
    Clin Infect Dis; 2007 Jan; 44(2):178-85. PubMed ID: 17173213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials.
    Falagas ME; Bliziotis IA; Fragoulis KN
    Am J Infect Control; 2007 Mar; 35(2):106-14. PubMed ID: 17327190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.
    Trampuz A; Murphy CK; Rothstein DM; Widmer AF; Landmann R; Zimmerli W
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2540-5. PubMed ID: 17502404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.